Salvaged Red Blood Cell Transfusion for Pancreatic Cancer

This trial explores the safety of using salvaged red blood cell transfusions during surgery for pancreatic cancer. The goal is to determine the frequency and timing of side effects, such as infections or transfusion reactions, after surgery. Participants will receive either their own salvaged blood or donor blood, depending on the available blood during surgery. This trial may suit individuals with confirmed pancreatic cancer who are preparing for surgery and do not have significant heart problems or active infections. As an unphased trial, it offers an opportunity to contribute to important research that could enhance surgical outcomes for future patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research shows that the Fresenius Kabi C.A.T.S®plus system, which reuses a patient's own blood during pancreatic surgery, is generally safe. This system collects and returns the patient's blood during the operation, reducing the need for donated blood. Studies on similar systems have found them to be well-tolerated, with few serious side effects.

When reviewing the use of a patient's own blood, researchers confirmed the quality and safety of the blood returned. Few unintended medical problems occurred, and those that did were mild. Common issues might include fever or mild allergic reactions, but serious problems are rare.

Researchers are excited about the use of the Fresenius Kabi C.A.T.S®plus Continuous AutoTransfusion System for pancreatic cancer surgery because it offers a unique approach to blood transfusion. Unlike standard transfusion practices that rely on donor blood (allogeneic transfusion), this system allows patients to receive their own salvaged blood (autologous transfusion) during surgery. This method minimizes the risk of transfusion-related complications, such as immune reactions and infections, and could potentially improve recovery outcomes. By reducing reliance on donor blood, this approach also addresses blood supply shortages, making it a promising advancement in surgical care for cancer patients.

This trial evaluates the effectiveness of the Fresenius Kabi C.A.T.S®plus system in using a patient's own blood during surgery. Participants in the autologous group will have their salvaged blood collected and returned, reducing the need for donor blood. Research has shown that this system maintains good levels of red blood cells and removes unwanted proteins, keeping the blood healthy. Using the patient's own blood lowers the risk of immune reactions or infections associated with donor blood. This method is considered a safe and promising option for patients undergoing pancreatic surgery.¹²³⁵⁶